|
|
||||||||
Division of Nephrology, Department of Medicine, Tupper Research Institute, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts
Correspondence: Bertrand L. Jaber, M.D., Division of Nephrology, New England Medical Center, 750 Washington St., Box 391, Boston, MA 02111. E-mail: bjaber{at}lifespan.org
The regulation of neutrophil apoptosis in chronic renal failure (CRF) has not been clearly defined. The Fas/FasL system is an important apoptotic regulatory pathway in a wide variety of cells. Fas is a widely expressed cell surface protein that transduces an apoptotic signal after interaction with its natural ligand FasL. In contrast to the extensive tissue distribution of Fas, constitutive expression of FasL is relatively limited. We examined Fas and FasL expression by neutrophils in healthy subjects, patients with CRF, and patients on hemodialysis (HD) and peritoneal dialysis (PD). Fas expression was significantly higher among patients with CRF compared with control subjects, HD patients, and PD patients. FasL expression was significantly higher among patients with CRF compared with control subjects. At 24 h, neutrophil apoptosis was higher among patients with CRF compared with control subjects. Furthermore, high-neutrophil Fas expression was paralleled by a higher sensitivity to Fas-mediated apoptosis. There was a strong correlation between Fas-stimulated apoptosis and creatinine clearance as well as Fas expression. Finally, we found that uremic serum increased the expression of neutrophil-associated Fas and FasL proteins, when compared with normal serum. Further studies are under way to examine the regulation of this pathway in the uremic environment.
Key Words: polymorphonuclear cells programmed cell death chronic renal failure toxins dialysis
This article has been cited by other articles:
![]() |
G. Cohen, J. Raupachova, T. Wimmer, R. Deicher, and W. H. Horl The uraemic retention solute para-hydroxy-hippuric acid attenuates apoptosis of polymorphonuclear leukocytes from healthy subjects but not from haemodialysis patients Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2512 - 2519. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sardenberg, P. Suassuna, M. C. C. Andreoli, R. Watanabe, M. A. Dalboni, S. R. Manfredi, O. P. dos Santos, E. G. Kallas, S. A. Draibe, and M. Cendoroglo Effects of uraemia and dialysis modality on polymorphonuclear cell apoptosis and function Nephrol. Dial. Transplant., January 1, 2006; 21(1): 160 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sela, R. Shurtz-Swirski, M. Cohen-Mazor, R. Mazor, J. Chezar, G. Shapiro, K. Hassan, G. Shkolnik, R. Geron, and B. Kristal Primed Peripheral Polymorphonuclear Leukocyte: A Culprit Underlying Chronic Low-Grade Inflammation and Systemic Oxidative Stress in Chronic Kidney Disease J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2431 - 2438. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Majewska, Z. Baj, Z. Sulowska, J. Rysz, and M. Luciak Effects of uraemia and haemodialysis on neutrophil apoptosis and expression of apoptosis-related proteins Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2582 - 2588. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |